



1

Quarantine-free travel between Hong Kong and mainland resumes

Normal travel between Hong Kong and Mainland China has resumed in phases starting 8 January, allowing up to 60,000 Hong Kong residents to enter the mainland each day via seven border checkpoints without the need for quarantine. Travellers to the mainland are required to [make bookings online](#) and obtain a negative result for a COVID-19 nucleic acid test conducted within 48 hours prior to entry. ([Xinhua](#))

2

Patent applications from Hong Kong get priority review in mainland

From 1 January, the China National Intellectual Property Administration (CNIPA) has implemented, on a trial basis, a priority review for all patent applications from Hong Kong residents and enterprises. The priority review of applications from Hong Kong entities can be requested through the Guangzhou or Shenzhen offices of the CNIPA. ([Nanfang Daily](#); in Chinese only)

3

Jiangmen establishes Hong Kong-Macao technology transfer centre

The Jiangmen-Hong Kong Enterprise Development Centre and the Jiangmen-Hong Kong-Macao Technology Transfer Centre are both now officially in operation. The two centres, both located in the Pearl River West InnoValley in Jiangmen, will provide support services to Hong Kong and Macao enterprises as a means of driving the “headquarters in Hong Kong or Macao, base in Jiangmen” and “research and development (R&D) in Hong Kong or Macao, technology transfer in Jiangmen” development models. ([Nanfang Daily](#); in Chinese only)

4

Mainland implements paperless registration of medical devices

Electronic registration for the certification of medical devices in Mainland China is now fully in force, covering domestic Class III as well as imported Class II and III devices. Enterprises must first register through the online service portal of the National Medical Products Administration (NMPA) website and get real-name authentication. Alternatively, they can log on to the NMPA app to register and download their electronic registration certificate. ([China News Service](#); in Chinese only)

5

Mainland announces reduced VAT on new list of drugs

The mainland recently made public a new list of anti-cancer and rare disease drugs that can now enjoy preferential value-added tax (VAT) treatment. Enterprises involved in the production, sale, wholesaling and retailing of the listed drugs will enjoy a reduced VAT rate of 3%. Similarly, enterprises importing drugs in these categories are eligible for a 3% reduction on import VAT. ([Xinhua](#); in Chinese only)